Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma (Q33392078)

26 July 2017

Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma (English)

1 reference

26 July 2017

0 references

Ufuk Abacioglu

1

0 references

Perran Fulden Yumuk

object named as

Perran F Yumuk

3

0 references

author name string

Hale B Caglar

2

1 reference

26 July 2017

Zuleyha Akgun

4

1 reference

26 July 2017

Beste M Atasoy

5

1 reference

26 July 2017

Meric Sengoz

6

1 reference

26 July 2017

29 September 2010

1 reference

Journal of Neuro-Oncology

26 July 2017

1 reference

26 July 2017

103

1 reference

26 July 2017

3

1 reference

26 July 2017

585-593

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-010-0423-2

26 July 2017

0 references

cites work

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Diagnosis and treatment of recurrent high-grade astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Advances in the treatment of primary brain tumors: dawn of a new era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Extended-schedule dose-dense temozolomide in refractory gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Bevacizumab plus irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0423-2

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

21 January 2018

1 reference

12 December 2020

Repair of O(6)-alkylguanine by alkyltransferases

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

Experience with irinotecan for the treatment of malignant glioma

1 reference

12 December 2020

Phase I trial of temozolomide using an extended continuous oral schedule.

1 reference

12 December 2020

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma

1 reference

12 December 2020

Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.

1 reference

12 December 2020

10.1007/S11060-010-0423-2

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference